A Phase II Study of MPDL3280A Alone or with Bevacizumab versus Sunitinib Alone in Patients with Previously Untreated Advanced Renal Cell Cancer

Full Title

A Phase II, Randomized Study of MPDL3280A Administered as Monotherapy or in Combination with Bevacizumab Versus Sunitinib in Patients with Untreated Advanced Renal Cell Carcinoma Back to top


MPDL3280A is an investigational drug designed to improve the immune system’s ability to recognize and destroy cancer cells by blocking PD-L1, a protein made by some cancers. In this study, researchers are evaluating the safety and effectiveness of giving MPDL3280A alone or in combination with bevacizumab in patients newly diagnosed with an advanced form of kidney cancer called renal cell carcinoma. Investigators are also comparing these two treatments with a third therapy, sunitinib, which is already used to treat renal cell cancer.

Patients in this study will be randomly assigned to receive one of these three treatments:

  • MPDL3280A alone
  • MPDL3280A with bevacizumab, which is also already used to treat renal cell cancer
  • sunitinib alone

MPDL3280A and bevacizumab are each given intravenously (by vein). Sunitinib is a capsule that is taken orally (by mouth).

Back to top


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have inoperable or metastatic renal cell carcinoma that has not been previously treated,
  • This study is open to patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Robert Motzer at 646-422-4312.

Back to top